Conditions: Plaque Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: yes

Brief summary:
This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild psoriasis. Part I and Part II in healthy participants will be initiated prior to Part III in psoriasis participants. The primary hypotheses of the study are: 1) that MK-0873 is safe and well tolerated in healthy participants and participants with psoriasis and 2) that the maximum plasma concentration of MK-0873 is \<20 nM in healthy participants and participants with psoriasis.

Detailed description:

Arms:
arm 1: In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days. arm 2: In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days. arm 3: In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days. arm 4: In Part II, healthy participants received skin application of placebo cream twice daily for 10 days. arm 5: In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days. arm 6: In Part II, healthy participants received skin application of placebo cream once daily for 10 days. arm 7: In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days. arm 8: In Part II, healthy participants received skin application of placebo cream twice daily for 10 days. arm 9: In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days. arm 10: In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.

Interventions: intervention 1: MK-0873 Patch intervention 2: MK-0873 Cream intervention 3: Placebo Patch intervention 4: Placebo Cream intervention 5: Plain patch
Intervention descriptions: intervention 1: MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873 intervention 2: MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873 intervention 3: Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches intervention 4: Placebo cream matching MK-0873 0.05%, 0.5%, or 2% intervention 5: Plain patch containing no MK-0873 or placebo

Protocol document: